The Evolution of Cellular Therapies in a New Clinical Research Environment
The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.
Animal Models Are Seeing Upgrades to Tackle Complex Molecule Testing
Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.
La Jolla Institute for Immunology Acquires Carterra LSA Platform
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries
Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.
Bio-Rad Expands Portfolio of Anti-Idiotypic Antibodies
Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.
Shimadzu’s Nexera XS Inert Chromatography System Enhances Biopharma Analysis
Shimadzu’s new ultra-high performance liquid chromatography system is designed to solve common problems in biopharma analysis.
Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test
Roche’s new test is the first available immunoassay that allows for simultaneous, independent determination of the hepatitis C virus antigen and antibody status.
Discovery Life Sciences Acquires AllCells
Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.
PerkinElmer Introduces New Cytometry Management Service
The PerkinElmer Flow Cytometry Instrument Concierge Services will provide biopharmaceutical labs with expert, on-site flow cytometry specialists.
Merck Digital Sciences Studio Supports Early-Stage Startups
Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.
Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA
Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.
